TAF15 (D8V6Q) Rabbit mAb #28409
- WB
- IP
- eCLIP
Supporting Data
| REACTIVITY | H M R Mk |
| SENSITIVITY | Endogenous |
| MW (kDa) | 77 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- eCLIP-eCLIP
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
- Mk-Monkey
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:100 |
| eCLIP | 1:200 |
Storage
Protocol
Specificity / Sensitivity
TAF15 (D8V6Q) Rabbit mAb recognizes endogenous levels of total TAF15 protein.
Species Reactivity:
Human, Mouse, Rat, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Arg584 of human TAF15 protein.
Background
TBP binding protein associated factor 15 (TAF15) is a member of the multifunctional FET (FUS, EWS, and TAF15) family of proteins that bind both DNA and RNA and may be important for transcriptional regulation and RNA processing (1,2). Research studies show that FET family proteins, including TAF15, can be found as oncogenic fusion proteins with transcription factors in a variety of cancers. The fusion protein consists of the FET protein amino-terminal transcription activation domain and the transcription factor DNA binding domain, creating an aberrant transcription factor with potent transactivation potential (1-3). TAF15 can be part of a subset of the transcription factor IID (TFIID) complex, indicating that it may form a transcription pre-initiation complex at active genes, even if it is not considered a canonical TAF (4,5). Additional studies suggest roles for TAF15 in RNA splicing through its association with U1 small nuclear RNA and in regulation of cell cycle regulatory gene expression through a mechanism involving miRNA biosynthesis (6,7).
- Law, W.J. et al. (2006) Brief Funct Genomic Proteomic 5, 8-14.
- Kovar, H. (2011) Sarcoma 2011, 837474.
- Bertolotti, A. et al. (1999) Oncogene 18, 8000-10.
- Bertolotti, A. et al. (1996) EMBO J 15, 5022-31.
- Bertolotti, A. et al. (1998) Mol Cell Biol 18, 1489-97.
- Jobert, L. et al. (2009) EMBO Rep 10, 494-500.
- Ballarino, M. et al. (2013) Oncogene 32, 4646-55.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.